| Literature DB >> 30881309 |
Marie Strickland1,2, Besma Yacoubi-Loueslati3, Balkiss Bouhaouala-Zahar4,5, Sylvia L F Pender2,6, Anis Larbi1,7,8,9.
Abstract
Aging is often associated with a loss of function. We believe aging to be more an adaptation to the various, and often continuous, stressors encountered during life in order to maintain overall functionality of the systems. The maladaptation of a system during aging may increase the susceptibility to diseases. There are basic cellular functions that may influence and/or are influenced by aging. Mitochondrial function is amongst these. Their presence in almost all cell types makes of these valuable targets for interventions to slow down or even reserve signs of aging. In this review, the role of mitochondria and essential physiological regulators of mitochondria and cellular functions, ion channels, will be discussed in the context of human aging. The origins of inflamm-aging, associated with poor clinical outcomes, will be linked to mitochondria and ion channel biology.Entities:
Keywords: aging; cellular senescence; inflammation; ion channels; mitochondria
Year: 2019 PMID: 30881309 PMCID: PMC6405477 DOI: 10.3389/fphys.2019.00158
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Voltage-gated and ligand-gated ion channel nomenclature.
| Gating classification | Channel family | Channel subunit/subfamily | Channel abbreviation |
|---|---|---|---|
| Voltage-gated ion | Voltage-gated sodium channel (Na+) | Alpha subunit | NaV1.1-1.9 |
| channel | Beta subunit | NaVβ1-4 | |
| Voltage-gated calcium channel (Ca2+) | L-type calcium channel (Long-lasting) | CaV1.1-1.4 | |
| P/Q-type channel (Purkinje/Unknown) | CaV2.1 | ||
| N-type channel (Neural) | CaV2.2 | ||
| R-type channel (Residual) | CaV2.3 | ||
| T-type channel (Transient) | CaV3.1-3.3 | ||
| Voltage-gated potassium channel | Alpha subunit | KV1-12 | |
| Beta subunit | KVβ1-3 | ||
| Hyperpolarization-activated cyclic nucleotide-gated (CNG) channels | Alpha subunit | CNGα1-4 | |
| Beta subunit | CNGβ1/3 | ||
| Voltage-gated proton channels | Hydrogen channel | HV1 | |
| Ligand-gated ion channel | Ionotropic glutamate receptors | α-amino -3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) | GluA1-4 |
| Kainate | GluK1-5 | ||
| GluN1, NRL1A-B, GluN2A-D, GluN3A-B | |||
| Orphan | GluD1-2 | ||
| Cys-loop receptors | Serotonin (5HT) | 5-HT3A-E | |
| Nicotinamide acetylcholine (nAChR) | α1-10, β1-4, γ, δ, ε | ||
| Zinc-activated ion channel (ZAC) | ZAC | ||
| α1-6, β1-3, γ1-3, δ, ε, π, θ, ρ1-3 | |||
| Glycine (GlyR) | α1-4, β | ||
| GABA receptors | GABAA receptor | α1-6, β1-3, γ1-3, δ, ε, π, θ | |
| 5-HT3 receptor | Serotonin | 5-HT3A-E | |
| ATP-gated channels | ATP-gated P2X receptor | P2X1-7 | |
| Phosphatidylinositol 4,5-biphosphate (PIP2)-gated channels | Inwardly rectifying potassium channel (Kir)-activating | Kir1.1-7.1 | |
Ionic channels and their age-related diseases by blocker/ligand matches (Guide to Immunopharmacology portal, http://www.guidetopharmacology.org/).
| Ionic channel subtypes | Age related diseases | Blockers/ligands | Reference |
|---|---|---|---|
| Transient receptor potential channels (TRP1, TRPM3) | Polycystic kidney disease 2; polycystic kidney disease 2-like 1 protein; | No putative TRP1 blockers Cd2+, Ni2+ ligands | |
| Voltage-gated potassium channels (Kv1.3) | Autoimmune diseases (i.e., diabetes, multiple sclerosis and rheumatoid arthritis) | Noxiustoxin; | |
| Charybdotoxin; | |||
| Margatoxin | |||
| Kaliotoxin | |||
| Maurotoxin | |||
| Voltage-gated calcium channels (Cav1.4) | Ocular albinism, ocular albinism type 2 | Dihydropyridine antagonists (verapamil, diltiazem) | |
| Calcium- and sodium-activated potassium channels (KCa2.3) | Parkinson disease | KCa2.3 blockers (Apamin, Leiurotoxin I) | |
| TRPV1 Transient receptor potential channels | Inflammatory bowel disease, Chron’s disease; Ulcerative colitis | Agatoxin | |
| TRPA1 Transient receptor potential channels | Inflammation, inflammatory pain and inflammatory diseases | Divalent cations modulators | |
| Cav2.2 Voltage-gated calcium channels | Renal and cardiovascular diseases | Omega-conotoxins | |
| Nav1.4 Voltage-gated sodium channels | Susceptibility to periods of hyperactivity | Saxitoxin | |
| Tetrodotoxin | |||
| Mu-conotoxins | |||
| Lidocaine | |||
| Kv8.1 Voltage-gated potassium channels | Epileptic disease | Kv8.1 is not functional on its own but modulates the properties of coexpressed Kv2.1 | |
| Cav1.3 Voltage-gated calcium channels | Multiorgan disease | Cd2+; Verapamil dihydropyridine antagonist | |
| Kv4.3 Voltage gated potassium channels | Àtrial Fibrillation, Valvular heart disease | Phrixotoxin 1 | |
| KCa2.1 Calcium- and sodium-activated potassium channels | Ataxia, epilepsy, memory disorders, pain and possibly schizophrenia and Parkinsons’s disease | NS8593 gating inhibitor | |
| Nav1.6 Voltage-gated sodium channels | Motor end-plate disease | α scorpion toxins | |
FIGURE 1Age-related changes in ion channel function. Calcium (Ca2+) release-activated Ca2+ channels increase intracellular Ca2+ levels, activating K+ channel opening and sustained Ca2+ signaling, whilst efflux of chloride (Cl-) ions inhibits Ca2+ influx. Downregulation of Ca2+ channels has been demonstrated in Alzheimer’s disease. Decreased expression of Ca2+-activated K+ channels have been noted with aging, particularly within the smooth muscle cells of the vascular system reducing arterial tone. Within the mitochondria, reduced Ca2+ ion channel activity results in reduced Ca2+ cycling. Potassium channel expression on the mitochondria are also reduced with age in the heart sarcolemma.
FIGURE 2Mitochondrial dysfunction during aging. Healthy mitochondria produce ROS through regular oxidative (OXPHOS) activity which aid in normal cell processes, this ROS production is kept in check by various anti-oxidant systems to prevent oxidative damage. During aging, dysfunctional mitochondria accumulate due to reduced biogenesis and ROS control. This increased ROS production induces both further mitochondrial damage and cellular damage, resulting in reduced cell function and eventual apoptosis.
Cytokines and their age-related-diseases.
| Age-related-diseases | Principal associated | cytokine | Reference |
|---|---|---|---|
| Sepsis | ↑ IL-6 level | → ↑ risk | |
| Alzheimer disease | ↑IL-6 Level | → ↑ risk | |
| ↑IL-1β level | |||
| ↓G-CSF | → ↑ risk | ||
| Cachexia syndrome | ↑TNFα level | → ↑ risk | |
| Dilated cardiomyopathy | ↑TNFα level | → ↑ risk | |
| Atherosclerosis and osteopenia | ↑IL-6 level | → ↑ risk | |
| ↑TNFα level | |||
| ↑ IL-1β level | |||
| Cognitive decline | ↑IL-6 level | → ↑ risk | |
| ↑TNFα level | |||
| Acute stroke | ↑IL-6 level | → ↑ risk | |
| ↑TNFα level | |||
| ↑ IL-10 level | →↓ risk | ||
| ↑ TGF-β level | |||
FIGURE 3(A) Ion channels and inflammation. Increased extracellular reactive oxygen species (ROS) stimulates TRPA1 and calcium (Ca2+) influx. This increases intracellular ROS production, MAPK activation and pro-inflammatory IL-8 release. Mitochondria produce ROS and ATP through their normal activities which affect ion flux, for example by increasing calcium influx into the cell by increasing calcium ion channel activity and stimulating further ROS production. In turn the secretion of inflammatory molecules such as IL-8 is stimulated. (B) Mitochondria, ions and inflammation. Mitochondria form the major platform for NLRP3 inflammasome assembly through the mitochondrial antiviral signalling protein (MAVS). Mitochondria activate this inflammasome complex by releasing damage associated molecular patterns (DAMPs) such as ROS and ATP leading to the maturation of IL-1β and IL-18 inflammatory molecules. Similarly, increased influx of ions such as calcium, chloride and potassium can also influence inflammasome activation.